ECSP982597A - DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA - Google Patents
DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINAInfo
- Publication number
- ECSP982597A ECSP982597A ECSP982597A ECSP982597A EC SP982597 A ECSP982597 A EC SP982597A EC SP982597 A ECSP982597 A EC SP982597A EC SP982597 A ECSP982597 A EC SP982597A
- Authority
- EC
- Ecuador
- Prior art keywords
- lower alkyl
- caused
- signify
- hydrogen
- cycloalkyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- -1 -N (R13) 2 Chemical group 0.000 abstract 2
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 2
- 206010034010 Parkinsonism Diseases 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000020564 Eye injury Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000010496 Heart Arrest Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 201000005040 opiate dependence Diseases 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El invento se refiere a compuestos de la fórmula general (gráfico), en donde R1 significa hidrógeno, alquilo inferior, fenilo o bencilo, R2 significa alquilo inferior, alcoxilo inferior, -O(CH2)Nn(R13) (R14), -(CH2)Nn(R13) (R14) o -N(R15)-(CH2)Nn(R13) (R14), R3-R12 significa hidrógeno, halógeno, trifluorometilo, alquilo inferior, cicloalquilo, alcoxilo inferior, hidroxilo, nitro, ciano, -N(R13)2, fenilo, feniloxilo, bencilo o benciloxilo, o R6 y R7 juntos significan un anillo de benceno, R13-R15 significan hidrógeno, alquilo inferior o cicloalquilo y n significa 1-5, así como sus sales farmacéuticamente aceptables. Estos compuestos son apropiados para el control o prevención de trastornos neurológicos agudos y/o crónicos, tal como función cerebral limitada causada por operaciones de bypass o transplantes, pobre riego sanguineo alcerebro, lesiones de médula espinal, lesión de la cabeza, hipoxia causada por gestación, paro cardiaco e hipoglicemia, enfermedad de Alzheimer, corea de Huntington ALS, demencia causada por SIDA, lesiones oculares, retinopatía, enfermedades cognitivas, parkinsonismo idiopático o parkinsonismo causado por medicamentos, asi como condiciones que conducen a funciones glutamato-deficientes, tal como, por ejemplo, espamos musculares, convulsiones, migraña, incontiencia urinaria, adicción a la nicotina, psicosis, adicción opiacea, ansiedad, vómitos, dolor crónico, diskinesia y depresiones.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982597 ECSP982597A (es) | 1998-07-17 | 1998-07-17 | DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982597 ECSP982597A (es) | 1998-07-17 | 1998-07-17 | DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982597A true ECSP982597A (es) | 1999-12-23 |
Family
ID=42043517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982597 ECSP982597A (es) | 1998-07-17 | 1998-07-17 | DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982597A (es) |
-
1998
- 1998-07-17 EC ECSP982597 patent/ECSP982597A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016129A1 (es) | Compuestos derivados de 5h-tiazolo[3,2-a]pirimidina; su uso, un procedimiento para prepararlos, medicamentos que los contienen y compuestos utiles comointermediarios | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| MY126586A (en) | Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands | |
| EP1458708A4 (en) | HETEROARYLSUBSTITUTED TRIAZOLE MODULATORS OF THE METABOTROPIC GLUTAMATAR RECEPTOR 5 | |
| EP1485093A4 (en) | METABOTROPIC GLUTAMATE RECEPTOR-5 DI-ARYL SUBSTITUTED TETRAZOL MODULATORS | |
| PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
| RU98114683A (ru) | Производные 5-н-тиазол[3,2-a]пиримидина | |
| MXPA05008212A (es) | Nuevos compuestos de arilpiperazinilo. | |
| PE20081462A1 (es) | Bifenilsulfonilos y fenil heteroaril sufonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
| CA2540768A1 (en) | Pyrazolo and imidazo-pyrimidine derivatives | |
| TR199802206T2 (xx) | Benzofuril t�revleri ve bunlar�n kullan�m�. | |
| IL105464A0 (en) | 1-piperazino-1,2-dihydroindene derivatives | |
| PE135299A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona | |
| BR0215801A (pt) | Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos | |
| WO1999059499A3 (en) | Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders | |
| ECSP982597A (es) | DERIVADOS DE 5H-TIAZOLO (3,2,a) PIRIMIDINA | |
| AU775656B2 (en) | Use of carbonylamino derivatives against CNS disorders | |
| BRPI0409307A (pt) | derivados de 3-azabiciclo[3.2.1]octano | |
| BR0308070A (pt) | Agonistas do receptor beta3 adrenérgico | |
| JP2009507052A (ja) | ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用 | |
| JP2000504730A (ja) | 製薬学的活性物質及び使用方法 | |
| US5500442A (en) | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants | |
| EP0299345A3 (en) | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | |
| MXPA04008880A (es) | Nuevos compuestos de benzoindolina, un proceso para su preparacion y las composiciones farmaceuticals que los contienen. | |
| TH40575A (th) | อนุพันธ์ 5H -ไธอะโซโล [3,2-3a] พิริมิดิน |